Tai long Pharmaceutical (600222) dynamic comment: half a year's performance is under pressure and the reform is marginal.
Tai long Pharmaceutical (600222): buy-back incentive is coming
Tai long Pharmaceutical (600222) Company dynamic comment: sign up Research Hospital Society for diversification, multi-level and mutual benefit and win-win situation
Tailong Pharmaceutical (600222) Annual Report Review: Steady Growth in Revenue and Increased Expenses Affect Profits
Tai long Pharmaceutical (600222) Quarterly report comments: traditional Chinese medicine preparation gradually rebounded business adjustment will continue
[Soochow Securities] Tai long Pharmaceutical Industry: traditional Chinese medicine preparations gradually pick up, business adjustment will continue
Comments on Tai long Pharmaceutical (600222): circulation business drags down overall performance and product structure adjustment
Tai long Pharmaceutical Industry (600222) comments: the main industry adjusts one core and two wings to develop rapidly
Tai long Pharmaceutical Industry (600222) in-depth study: new listing structure adjustment of natural plant drinks waiting for performance to pick up
[Soochow Securities] Tai long Pharmaceutical Industry: natural plant drinks are newly listed, structural adjustment is waiting for performance to pick up.
Comments on Tai long Pharmaceutical (600222): internal Integration affects short-term performance growth
Tai long Pharmaceutical (600222): the future development strategy of increasing the holdings of major shareholders is clear
[Huachuang Securities] Tai long Pharmaceutical Co., Ltd.: project acceleration, 15 years ushered in performance valuation flying together
[Fangzheng Securities] Tailong Pharmaceutical: M&A fund plans to invest in Hebang Biotech to lay out protein and peptide drugs
[Shenwan Hongyuan] Tailong Pharmaceutical: Participating companies invest abroad and strategically lay out biopharmaceuticals
太龙药业(600222)公司动态跟踪报告:参股公司对外投资 战略布局生物药
[Southwest Securities] Tailong Pharmaceutical 2014 Annual Report Review: Product Structure Adjustment, Gross Margin Gradually Rises
[Shenwan Hongyuan] Tailong Pharmaceutical: Steady operation, both endogenous and epitaxial
太龙药业(600222)年报点评:经营稳健 内生和外延均有看点
[Fangzheng Securities] Tailong Pharmaceutical: The completion of mergers and acquisitions opens a new era, opening up a new world of traditional Chinese medicine
No Data